News
Oct 2023
In collaboration with UCLA and MD Anderson, EarlyDx has been awarded a NIH U01 grant on "Multi-cancer early detection using cell-free DNA methylome analysis". With this award, EarlyDx will join the NIH Liquid Biopsy Consortium.
Sep 2023
EarlyDx has been awarded a NIH SBIR Phase II contract on building a cloud-based Liquid-biopsy and Radiomics Platform for early cancer detection.
Jul 2023
EarlyDx published Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.
Proc Natl Acad Sci USA. 2023 Jul;120(28):e2305236120.
News highlight by UCLA news, The Medical News, Drug Target Review, Medical Xpress, and Healthcare in Europe.
Check media coverage summary.
Sep 2022
Our technology on using cfDNA methylome to detect cancer has been published in Nature Communications!
News link:
[UCLA News]
[GenomeWeb]
[HemOnc Today]
[ScieneDaily]
[Biocompare]
Sep 2022
EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.
May 2022
EarlyDx announced the appointment of Guanghui Hu as co-CEO.
May 2022
EarlyDx published cfTrack: Non-invasive monitoring of cancer MRD, Recurrence, and Evolution in Clinical Cancer Research.
Sep 2021
EarlyDx Awarded an NIH SBIR Phase I Contract on the Further Development of the Cloud Computing Platform for Liquid Biopsy.
April 2021
Co-founder Jasmine Zhou presented EarlyDx’s CancerRadar Technology and Clinical Data in Oral Presentation at AACR Annual Meeting 2021 on April 10, 2021.
May 2020
EarlyDx Awarded an NIH SBIR Phase I Grant for Assay Development.
Feb 2020
EarlyDx closed $5M Series Seed-1 Fundraising Led by Alpha Edison.
May 2019
EarlyDx Exhibits its One-Stop Shop Bioinformatics Platform, EarlyDx-Cloud, at 2019 ASCO Annual Meeting.